# Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS)

> **NCT03369665** · PHASE4 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 485 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Mavenclad®

## Key facts

- **NCT ID:** NCT03369665
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-20
- **Primary completion:** 2021-11-12
- **Final completion:** 2021-11-12
- **Target enrollment:** 485 (ACTUAL)
- **Last updated:** 2023-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03369665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03369665, "Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03369665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*